# Alentis Therapeutics

> Alentis Therapeutics is a Swiss clinical-stage biotech built around a single, unusual biological target: Claudin-1 (CLDN1), a tight-junction protein that becomes exposed in both fibrotic tissue and solid tumors. Founded in 2019 on the discovery of physician-scientist Professor Thomas Baumert, the company develops first-in-class monoclonal antibodies and antibody-drug conjugates that bind exposed CLDN1 to reverse organ fibrosis and treat CLDN1-positive cancers. Headquartered in Allschwil near Basel with R&D roots in Strasbourg, Alentis has raised roughly $365 million across rounds, including a $181.4 million Series D in November 2024, and is running clinical trials for its lead antibody lixudebart (ALE.F02) and two ADCs, ALE.P02 and ALE.P03.

- **Founded:** 2019
- **Headquarters:** Allschwil (Basel), Switzerland
- **Founders:** Thomas Baumert (Founder & Scientific Founder (physician-scientist, University of Strasbourg / Inserm))
- **Team size:** Approx. 68 employees (reported); company states over 50
- **Products:** Lixudebart (ALE.F02), ALE.P02, ALE.P03
- **Notable:** Raised an oversubscribed $181.4 million Series D in November 2024, one of the larger European biotech rounds of the year., Total funding of roughly $365 million since 2019., FDA IND clearance and Fast Track designation for ALE.P02, a first-in-class CLDN1 ADC for squamous cancers.

## Products & services

- **Lixudebart (ALE.F02)** — Lead first-in-class anti-Claudin-1 monoclonal antibody for organ fibrosis - kidney, liver and lung - and ANCA-associated vasculitis. In Phase 1/2 trials; FDA Orphan Drug designation for idiopathic pulmonary fibrosis (IPF).
- **ALE.P02** — First-in-class anti-Claudin-1 antibody-drug conjugate (ADC) targeting CLDN1-positive squamous solid tumors, including head and neck squamous cell carcinoma. In Phase 1/2; received FDA IND clearance and Fast Track designation.
- **ALE.P03** — Anti-Claudin-1 antibody-drug conjugate for CLDN1-positive solid tumors, in first-in-human Phase 1 development.

## Achievements

- Raised an oversubscribed $181.4 million Series D in November 2024, one of the larger European biotech rounds of the year.
- Total funding of roughly $365 million since 2019.
- FDA IND clearance and Fast Track designation for ALE.P02, a first-in-class CLDN1 ADC for squamous cancers.
- FDA Orphan Drug designation for lixudebart in idiopathic pulmonary fibrosis.
- Preclinical proof-of-concept for Claudin-1 antibodies published in Science Translational Medicine.
- Founder Thomas Baumert awarded the INSERM Research Prize in 2023.
- Recruited Mark Pruzanski (founder of Intercept Pharmaceuticals) as CEO in October 2025.

## Latest updates

- **2025-10** — Mark Pruzanski, founder of Intercept Pharmaceuticals and former CEO of Versanis Bio, appointed CEO, succeeding Roberto Iacone.
- **2024-11** — Closed an oversubscribed $181.4M Series D led by OrbiMed with Novo Holdings and Jeito Capital as co-leads, to fund Phase 1/2 trials of ALE.P02 and ALE.P03.
- **2024** — Received FDA Orphan Drug designation for lixudebart in idiopathic pulmonary fibrosis.

## Links

- Website: https://alentis.ch
- LinkedIn: https://www.linkedin.com/company/alentis-therapeutics
- YouTube: https://www.youtube.com/channel/UCTH5dLP_r1eN6zaujt7vaew

---

Profile page: https://yespress.io/alentis-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-16